Adel M. Talaat has taken the leap from Ph.D. to CEO, and expanded his acronym awareness from ADGE (array differential gene expression) to SBIR (Small Business Innovation Research).
An associate professor in UW-Madison’s Department of Pathobiological Sciences, he became chief executive officer of Pan Genome Systems Inc. That was in August 2011. Less than a year later, the U.S. Department of Agriculture awarded the company an SBIR grant to develop vaccine candidates to prevent and control Johne’s disease. In addition, Talaat has secured a contract from Saudi Arabia to work on a vaccine specifically for camels.
Johne’s disease causes an estimated $500 million economic loss per year in the United States. Pronounced “YOH-nees,” Johne’s disease is also known as paratuberculosis, reflecting the bacterium that causes the fatal contagious gastrointestinal disease.
The disease affects “ruminant” animals such as cattle, sheep, goats, deer, antelope, bison and camels. The University of Wisconsin School of Veterinary Medicine estimates that 68% of dairy herds in the United States have at least one infected animal.
That explains why the USDA awarded the $100,000 grant to help Pan Genome Systems commercialize university-based research. Talaat had assistance along the way from the Wisconsin Entrepreneurs' Network (WEN). WEN, now the Center for Technology Commercialization (CTC), is one of two programs managed by UW-Extension’s entrepreneurship and economic development division.
“WEN was a great resource for me when I started my business,” Talaat said, specifically referring to Cheryl Vickroy, who now serves as the CTC's Director. “Without the help of WEN and Cheryl, I would not have been able to start this business. Cheryl was very instrumental in my decisions on how to start the business, how to hire people, how to find a location for the business and how to go about grant writing and soliciting funding from federal agencies and venture capitalists.”
While Johne’s disease is the corporation’s first focus, Talaat explained that Pan Genome System’s work could develop better diagnostics and vaccines to serve both human and animal health.